Symptomatic treatment of recurrent dyspeptic disorders not related to organic gastrointestinal disease, such as heartburn, hyperacidity of gastric juice, epigastric pain.
Composition:
1 tabl effervescent contains 150 mg Ranitidine as hydrochloride; tablets contain aspartame, sodium and sodium benzoate.
Action:
Competitive and reversible histamine H receptor antagonist2. It inhibits the basic and stimulated secretion of hydrochloric acid by the parietal cells of the stomach (for 12 hours). The increase in pH is probably also related to the direct action of the excipients present in the effervescent tablet: sodium citrate and sodium bicarbonate, which act buffered the stomach content as early as a few minutes after drug administration. The bioavailability of ranitidine after oral administration is approximately 50%, Cmax occurs in about 2 hours, binding to plasma proteins - 15%. Ranitidine passes through the cream-brain barrier, the placenta barrier and is excreted into breast milk. It is partially metabolised in the liver (to a large extent during the first pass); the major metabolites are: N-oxide, S-oxide and demethylarganitidine. It is excreted mainly in the urine, in unchanged form and in the form of metabolites. T0,5 it is about 2.5 hours; it is longer in patients with renal failure and in elderly patients.
Contraindications:
Hypersensitivity to ranitidine or other ingredients of the preparation. Liver cirrhosis with portal hypertension. Phenylketonuria. Children aged <16 years.
Precautions:
Before starting treatment of peptic ulcer, the neoplastic nature of the lesions should be ruled out, because treatment with ranitidine may mask the symptoms of the neoplastic disease and delay the diagnosis. Use with caution in patients with impaired hepatic or renal function and in the elderly. Avoid use in patients with a history of acute porphyria. It is not recommended to administer the drug simultaneously with substitution therapy with pancreatic enzymes or in acute pancreatitis. Use with caution in patients treated with anticoagulants or NSAIDs. Smoking reduces the effectiveness of the drug. The sodium content should be taken into account when using the drug in people on a controlled sodium diet. Sodium benzoate contained in the preparation may cause allergic reactions and asthma attacks in patients with asthma.
Pregnancy and lactation:
Use only in case of extreme necessity. Use during breastfeeding is not recommended (ranitidine is excreted in human milk and may inhibit gastric secretion, inhibit drug metabolism and stimulate the central nervous system of a breast-fed newborn).
Side effects:
Most often: headache, upper respiratory tract infections, runny nose, influenza, flu-like symptoms, nausea, vomiting, diarrhea, epigastric pain, flatulence, belching, taste disturbances. After doses of 150-300 mg / day may occur: confusion, restlessness, visual and auditory hallucinations (nervous system activities are more severe at high doses, in people> 65 years and in patients with chronic renal failure and ( liver), bradycardia, atrioventricular block, tachycardia, hypersensitivity reactions (urticaria, angioneurotic edema, bronchospasm, fever, hypotension, rash), anaphylactic reactions, urticaria combined with facial edema and laryngeal spasm, Stevens-Johnson syndrome. Also observed were: leukopenia, granulocytopenia, thrombocytopenia, erythema multiforme and pruritus. In single cases: gynecomastia, impotence, lower libido in men, transient increase in liver enzymes, transient hepatitis, transient hypergastrinemia, increase in creatinine.
Dosage:
Orally. Adults and adolescents from 16 years: for recurrent dyspeptic symptoms, 150 mg should be taken, if necessary twice daily. Do not use more than 300 mg / day. If the symptoms do not subside after 2 weeks of treatment, the diagnosis should be verified.Special groups of patients. In patients with renal failure, a 2-3-fold T lengthening is observed0,5 and a decrease in plasma clearance by 80%; in patients on dialysis, the drug should be administered after dialysis. In liver failure, there is no need to change the dosage of the drug. In patients> 65. it is possible to extend the T two times0,5; consideration should be given to reducing the dose.Way of giving. Before using the tablet, dissolve in 100 ml of water and drink the solution after completely dissolving the preparation.
(C)
